Immunome vs Upstream Bio
IMNM and UPB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IMNM and UPB compare
Immunome is the larger company, worth 11 times as much as Upstream Bio ($2.1B against $187M).
Upstream Bio grew revenue faster over the last twelve months (16.0% versus −63.3% for Immunome).
Upstream Bio keeps more of each dollar of sales as profit, with a net margin of −4956% compared with −5594% at Immunome.
Upstream Bio scores higher on the StockData Score (9 against 7 for Immunome), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IMNM | UPB |
|---|---|---|
| Size and price | ||
| Market cap | $2.1B | $187M |
| Share price | $18.21 | $3.41 |
| Change, 1 year | 15.5% | −85.9% |
| Change, 5 years | −11.7% | – |
| Beta (5Y) | 1.77 | 1.47 |
| Employees | 177 | 75 |
| StockData Score | ||
| Total score | 7 | 9 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 1 (better) |
| Performance score | 1 | 1 |
| Health score | 6 | 6 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 515× | 59.1× (better) |
| P/B | 3.5× | 0.7× (better) |
| FCF yield | −9.9% | – |
| Growth | ||
| Revenue growth (TTM) | −63.3% | 16.0% (better) |
| Profitability | ||
| Operating margin | −5948% | −5383% (better) |
| Net margin | −5594% | −4956% (better) |
| FCF margin | −5119% | – |
| Return on equity | −50.1% | −46.0% (better) |
| Return on invested capital | – | −1082% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 21.68 | 27.99 (better) |
| Altman Z-score | 37.96 (better) | 8.07 |
| Piotroski F-score | 4 (better) | 1 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 104% | 92.3% |
| Held by insiders | 6.4% | 8.6% |
| Insider net buying, 12 months | −$25.2M | −$105K (better) |
| Short interest, % of float | 15.8% | 9.0% |
Go deeper
- IMNM stock overview
- IMNM income statement
- IMNM valuation and score
- UPB stock overview
- UPB income statement
- UPB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.